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The renin–angiotensin system (RAS) is a major regulator of renal fibrosis. Besides
the classical renin/Angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/AT1
and AT2 axis, multiple new axes have been recently described. The new members
have added new dimensions to RAS, including the ACE2/Ang(1–7)/Mas receptor axis,
the prorenin/(pro)renin receptor(PRR)/intracelluar pathway axis, and the Angiotensin A
(Ang A), alamandine-Mas-related G protein coupled receptor D(MrgD) axis. This review
summarized recent studies regarding role of the non-classical RAS axis in renal fibrosis,
and its possible implications to the intervention of progression of chronic kidney disease.
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Introduction
Glomerulosclerosis and tubular interstitial fibrosis are the final common manifestation of a wide
variety of chronic kidney diseases (Liu, 2006). One common feature of progressive renal disease
is the proliferation of resident renal cells, excessive accumulation and deposition of extracellular
matrix (ECM), and tissue retraction (Eddy, 2014). The renin–angiotensin system (RAS) is a major
regulator of renal fibrosis (da Silveira et al., 2010). Both tissue and circulatory RAS are believed to be
overactivated in the development of renal fibrosis (Navar, 2014). Tremendous studies have demon-
strated that angiotensin II (AngII) play a powerful role in renal fibrosis by mediating the release of
transforming growth factor-β (TGF-β) and activating inflammatory process (Mezzano et al., 2001).
Moreover, our previous studies have suggested connective tissue growth factor (CTGF)/integrin-
linked kinase (ILK) participated in the renal fibrosis development mediated by AngII (Liu et al.,
2007). We also proposed the interaction of AngII and inflammation might be the critical node
in pathogenic glomerulotubular feedback loop (Zhang and Liu, 2011). In addition to angiotensin-
converting enzyme (ACE) dependent AngII generating system, chymase as an alternative AngII
generating enzyme, was involved in the development of diabetic/hypertensive nephropathy (Huang
et al., 2003). However, in recent years, RAS is far more complex than originally described (Chappell,
2012). New members have been added to the RAS family, which played critical roles in the process
of renal diseases (Chappell, 2012; Simoes e Silva et al., 2013). This review will focus on the role
of new RAS members and the mechanism in promoting glomerulosclerosis and tubularinterstitial
fibrosis.
ACE2/Ang(1–7)/Mas Receptor Axis
Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase. ACE2 converts angiotensin
II (Ang II) to angiotensin 1–7 [Ang(1–7)], which binds to Mas (Vickers et al., 2002). ACE2 shares
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40–42% homology with ACE but shows different biochemical
activities (Donoghue et al., 2000). ACE and ACE2 co-localize in
the brush border of mouse proximal tubules (Ye et al., 2006).
However, they localize to different cell types in glomeruli. Within
the glomerulus, ACE2 is present in glomerular epithelial cells and
glomerular mesangial cells. Glomerular ACE is mainly expressed
in endothelial cells. In contrast to the fibrogenic and prolif-
erative actions of the ACE/Ang II/AT1 axis, it has been sug-
gested that the ACE2/Ang(1–7)/Mas axis exerts anti-fibrogenic
and anti-proliferative actions (Ferrario, 2011).
ACE2 and Renal Fibrosis
Many studies have suggested a protective role for ACE2 in
different models of renal damage or diseases, including subto-
tal nephrectomy (Dilauro et al., 2010), ischaemia/reperfusion
kidney injury (da Silveira et al., 2010), unilateralureteral obstruc-
tion (UUO) (Liu et al., 2012). Acquired genetic ACE2 defi-
ciency accelerates renal injury in those experimental models.
Dilauro et al. reported that kidney ACE2 is downregulated in
the early period after 5/6 nephrectomy (5/6 NX). Inhibition of
ACE2 with MLN-4760 (MLN) in 5/6 NX mice increases albu-
minuria via an AT1 receptor dependent mechanism, indepen-
dent of blood pressure (Dilauro et al., 2010). In studies from
Zhong et al., wild-type mice were infused with Ang II and treated
daily with recombinant human ACE2. It showed that ACE2
could attenuate Ang II-induced pressor response and normal-
ize renal Ang II levels and oxidative stress. Importantly, ACE2
could prevent Ang II-induced tubulointerstitial fibrosis (Zhong
et al., 2011). Regarding glomerularsclerosis, it has been shown
that glomerular staining for fibronectin was increased in both
db/db and db/m mice that were treated with ACE2 inhibitor
(MLN-4760) compared with vehicle-treated group (Ye et al.,
2006).
ACE and ACE2 activity play an important role to balance the
expression of angiotensin II and angiotensin(1–7) (Chappel and
Ferrario, 2006). The integral relationship of ACE/ACE2 is criti-
cally involved in process of renal fibrosis. Our previous study has
suggested that treatment of HK-2 cells to bovine serum albumin
(BSA) led to a significant dysregulation of ACE/ACE2 expression
in time and concentration dependent manner (Liu et al., 2009).
However, in a recent study with cultured podocytes, insulin
increases ACE2 expression and favors an “anti-angiotensin II”
regarding ACE/ACE2 gene expression balance and decreases
fibronectin expression as a marker of fibrosis. In the presence
of albumin, the effect of insulin on ACE2 disappeared. The
authors suggest that albuminuria might block the beneficial effect
of modulating RAS balance for preventing diabetic nephropa-
thy (Marquez et al., 2014). Moreover, urinary albumin excretion
(UAE) increased significantly in ACE2 inhibitor-treated group
as compared with vehicle-treated db/db mice (Ye et al., 2006).
These studies suggested the close correlation between albumin
and ACE2. ACE2 reduction could accelerate albuminuria, while
albumin in turn could disrupt the balance of ACE/ACE2. The
interplay between ACE and ACE2 may govern the formation and
metabolism of Ang effector peptides, the regulators that deter-
mines their balance need more studies (Brosnihan et al., 2005).
Moreover, it is still unclear whether the protective effects of ACE2
is due to the reduction of AngII, the formation of Ang(1–7) or the
increased ratio of Ang(1–7) to AngII.
Transforming growth factor-β1 (TGF-β1) is a key media-
tor in the process of renal fibrosis (Lan and Chung, 2012).
The interaction between TGF-β and ACE2-Ang(1–7)-Mas has
been observed. In NRK-52E cells, TGF-β1 decreases ACE2
and Mas and Ang(1–7) conversion from Ang II. The com-
bination of Ang-(1–7) and Mas could attenuate TGF-β1 (but
not high glucose)-induced fibronectin (Chou et al., 2013). Liu
et al. showed that deletion of ACE2 resulted in increasing
ratio of intrarenalAng II/Ang(1–7) and enhanced renal fibro-
sis in the UUO nephropathy. These changes were attributed
to the increase in the intrarenalAng II signaling (AT1-
ERK1/2 mitogen-activated protein kinase), TGF-β/Smad2/3,
and NF-κB signaling pathways. The authors concluded that
enhanced AngII-mediated TGF-β/Smad and NF-κB signal-
ing might be one of the mechanisms by which loss of
ACE2 enhances renal fibrosis and inflammation (Liu et al.,
2012).
Ang(1–7) and Renal Fibrosis
Multiple small peptides can be derived from degradation of AngII
and have been demonstrated to have local physiological effects in
the kidney. Those peptides include Ang(1–7) (Alzayadneh and
Chappell, 2014), Ang(2–8) (Kemp et al., 2012), Ang(3–8) (Chai
et al., 2004), Ang(3–4) with Ang(1-5), and Ang(1–4) as inter-
mediate peptides (Axelband et al., 2009). Among those peptides,
Ang(1–7) is a biologically active heptapeptide from the degrada-
tion of angiotensin II by ACE2, the role of which in kidney disease
have been studied most extensively (Ferrao et al., 2014). Santos
et al. firstly found a G protein-coupled receptor for Ang(1–7),
the Mas receptor. It provides the molecular basis for the phys-
iological actions of this peptide (Santos et al., 2003). Although
there is now much evidence that Ang(1–7) may exert a protec-
tive role in experimental models of renal diseases, a few stud-
ies have revealed controversial results. Consequently, the role of
Ang(1–7) in the progression of CKD requires further clarifica-
tion, especially its therapeutic role in different types of kidney
diseases.
Ang(1–7) has been demonstrated to be able to ameliorate
streptozotocin induced diabetic renal injury. In mouse model
of streptozotocin induced diabetic nephropathy, large dose of
Ang(1–7) improved renal function, attenuated glomeruli sclero-
sis, oxidative stress, and cell proliferation (Zhang et al., 2015).
Moreover, the effects of large-dose Ang(1–7) alone and in com-
bination with valsartan were superior to valsartan alone, but
the combination had no significant synergistic effect compared
with Ang(1–7) alone (Zhang et al., 2015). Mori et al. adminis-
tered Ang(1–7) or saline to 5-mo-old db/db mice. The treatment
reduced kidney weight and amelioratedmesangial expansion and
increased urinary albumin excretion. The protective effect on
renal fibrosis was correlated with dephosphorylation of the sig-
nal transducer and activator of transcription 3 (STAT3) pathway
(Mori et al., 2014).
In contrast, another study using a moderate dose of Ang(1–7)
to treat diabetic nephropathy showed no benefitial effect in
reducing the levels of serum creatinine and creatinine clearance
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(Singh et al., 2010). Shao et al. reported that treatment of STZ
induced diabetic rat by constant Ang(1–7) vein injection for 6
weeks, renal function was found to be even worse than dia-
betic rats (Shao et al., 2008). In the 5/6 NX mouse model of
chronic kidney disease (CKD), treatment of 5/6 NX mice with
Ang(1–7) increased kidney and plasma levels of Ang(1–7) but did
not change levels of blood pressure, urinary albumin excretion
(Dilauro et al., 2010).
The underlying mechanism for Ang(1–7)’s role in renal fibro-
sis needs to be further clarified before the therapeutic role
to be determined. A few studies have explored the molecu-
lar mechanisms of the renoprotection induced by Ang(1–7).
Alzayadneh et al. found that Ang(1–7) could abolish Advanced
glycation end products (AGEs)-induced activation of the MAP
kinase ERK1/2 to a similar extent as the TGF-β receptor kinase
inhibitor (Alzayadneh and Chappell, 2014). Ang(1–7) could also
decrease the expression of collagen IV, TGF-β1, VEGF, NOX4,
p47phox, PKCα, and PKCβ1, and the phosphorylation of Smad3
(Zhang et al., 2015). AGEs exposure in NRK-52E renal epithe-
lial cells for 48 h significantly reduced the intracellular lev-
els of Ang(1–7) approximately 50%. Treatment with Ang(1–7)
could reverse AGEs-induced cellular hypertrophy and myofi-
broblast transition (Alzayadneh and Chappell, 2014). Hyper-
lipidemia is an independent risk factor for renal disease, and
lipid deposition is closely correlated with glomerulosclerosis.
Huang et al. found that Ang(1–7) could inhibit low-density
lipoprotein accumulation and decreases cholesterol levels via
modulating the low-density lipoprotein receptor (LDLr) -sterol
regulatory element-binding protein (SREBP)-cleavage activat-
ing protein (SCAP) negative feedback system through the Mas
receptor (Shao et al., 2008). Interestingly, Ang(1–7) antagonize
the effect of Ang II on lipid accumulation. Our previous stud-
ies showed that Ang II increased lipid droplet accumulation in
human renal mesangial cells (HMCs) via enhanced translocation
of the SCAP/SREBP-2 complex from the endoplasmic reticulum
(ER) to the Golgi in HMCs (Ma et al., 2013). Since the close cor-
relation between renal lipid accumulation and glomerulosclero-
sis, tubulointerstitial fibrosis, especially in diabetic kidney disease
has been shown, we thought that Ang(1–7) might prevent the
progression of renal fibrosis through its inhibition on lipid accu-
mulation (Wang et al., 2005). This could be a interesting aspect
in exploring the therapeutic role of Ang(1–7) in treating renal
fibrosis.
Consequently, to address the theraputic potential of Ang(1–7),
the related issues that need to be clarified include: (1) the effect of
different doses of Ang(1–7); (2) the effect of its combination with
an angiotensin receptor blocker; (3) the mechanism by which it
exerts the protective effect.
Prorenin/(pro)renin Receptor
(PRR)/intracellular Signaling Axis and
Renal Fibrosis
A new axis in the RAS research field provoking much interest
recent years is the prorenin/PRR/intracelluar pathway axis. Renin
is synthesized in juxtaglomerular cells of the afferent arterioles
of the kidney as preprorenin. Prorenin was generated by cleav-
age of a 23 amino acid peptide at carboxyl terminus of pre-
prorenin. Prorenin is activated to renin by cleavage of 43-amino
acid N-terminal prosegment by proteases (Song and Yosypiv,
2011). The receptor binding renin and prorenin, named the PRR,
was cloned in 2002 (Nguyen et al., 2002). The binding induces
prorenin enzymatical activation without cleavage of the proseg-
ment, and triggers intracellular signaling pathways independent
of the RAS. Through activating multiple intracellular pathways,
prorenin/PRR participate in the development of renal fibrosis
independent of ANG II. Recent findings have found additional
role of PRR, participating in the functions of vacuolar proton
ATPase and constituting the Wnt receptor complex (Oshima
et al., 2014). The novel biological effect of PRR is that it regu-
lated several cellular homeostatic processes including autophagy
which was described in a recent review (Binger andMuller, 2013).
Prorenin/PRR in Resident Kidney Cells
In multiple types of resident kidney cells, it has been shown
that prorenin/PRR could activate several intercellular signal-
ing pathways leading to renal fibrosis. In the human kidney,
confocal microscopy has identified that the PRR localized in
mesangium of glomeruli and in the subendothelium of coro-
nary and kidney artery (Nguyen et al., 2002). However, a num-
ber of studies showed predominant expression of PRR in the
collecting duct, particularly on the apical membrane of inter-
calated cells (Advani et al., 2009; Gonzalez et al., 2013). Thus,
the cellular localization of PRR in addition to its molecular
form is intriguing. The protein is shown to accumulate intra-
cellular or in plasma membrane or in the trans-Golgi. Indeed,
Prieto et al. found that hyperglycemia induces PRR trafficking
alterations and increase PRR abundance in plasma membrane
(PM) in the collecting duct. Recent evidence demonstrated that
PRR is predominantly activated by AngII, which is mediated by
(cycloxygenase-2) COX-2/E-prostanoid4 pathway (Wang et al.,
2014a,b).
In renal mesangial cells, Zhang et al. showed that elevated
prorenin could be activated through receptor binding with-
out being proteolytically converted to renin. This activation
leads to increased expression of PAI-1 and transforming growth
factor-β1 via AngII-independent and AngII-dependent mech-
anisms (Zhang et al., 2012). Melnyk et al. also showed that
two distinct pathways were activated by renin and prorenin, a
TGF-dependent pathway and a TGF-independent pathway (Mel-
nyk et al., 2009). Additionally, high glucose exposure enhanced
TGFβ1-CTGF signaling cascade through PRR (Huang et al.,
2011). In renal epithelial cell, Saito et al. demonstrated that
indoxyl sulfate, which is a uremic toxin, could induce expres-
sion of PRR and prorenin. PRR knock-down inhibited indoxyl
sulfate-induced expression of TGF-β1 and α-smooth muscle
actin in HK-2 cells. The up-regulation of prorenin expres-
sion and activation of PRR was related with reactive oxygen
species and activation of Stat3 and nuclear factor-κB (Saito et al.,
2014). In human embryonic kidney cells (HEK), both renin
and prorenin stimulate TGF-β, fibronectin and PAI-1 expres-
sion via a Nox4 dependent mechanism. The study indicates
a PRR/Nox4 pathway in the development of kidney fibrosis
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through the generation of superoxide anions (Clavreul et al.,
2011).
Thus, prorenin and PRR participate to an overall switch
toward a pro-fibrotic state of the kidney cells, including renal
mesangial cells, proximal tubular cells and embryonic kid-
ney cells. Prorenin/PRR could induce multiple pathways of
intercellular signaling via AngII-independent mechanism, lead-
ing to the development of renal fibrosis (Ichihara et al.,
2006a).
Prorenin/PRR in Animal Models
Activation of PRR by prorenin have been implicated in the
development and progression of renal fibrosis in animal models.
Kaneshiro et al. showed that in (pro)renin receptor-transgenic
rat, proteinuria and significant glomerulosclerosis was devel-
oped. In kidney, mitogen-activated protein kinases (MAPK) were
activated and expression of TGF-β1 was enhanced, and these
changes were AngII-independent (Kaneshiro et al., 2007). Ichi-
hara et al. showed that in AT1a receptor-deficient (ATKO) mice,
prorenin/PRR/MAP kinases ERK1/2 axis plays a pivotal role
in the development of diabetic nephropathy. Treatment of the
diabetic WT or ATKO mice with ACE inhibitor failed to pre-
vent the diabetic nephropathy completely, while chronic infu-
sion of mouse HR decoy peptide (HRP) (HRP inhibits prorenin
binding to PRR and non-proteolytic activation) (Ichihara et al.,
2004) completely prevented the increase in urinary protein excre-
tion and the development of glomerulosclerosis (Ichihara et al.,
2006b). In spontaneously hypertensive rats (SHR), inhibition of
non-proteolytic activation of prorenin by HRP decreased renal
AngII levels and attenuated the development and progression
of proteinuria and glomerulosclerosis, the effect is independent
of circulating RAS or arterial pressure (Ichihara et al., 2006a).
These findings suggest that prorenin/PRR may induce renal
fibrosis through multiple intracellular signaling, either alone or
in concert with activation of renal tissue RAS.
However, a recent study indicated that increased expression
of PRR is not sufficient to induce renal injury. Rosendahl et al.
generated a mouse that constitutively overexpressed PRR, they
found no difference in systolic blood pressure or albuminuria
between wild type and PRR overexpressing mice. And no renal
or cardiac fibrosis was detected with histological examination in
mutant mice. The authors suggest that PRR might not play cen-
tral role in organ damage per se (Rosendahl et al., 2014). Interest-
ingly, transgenic overexpression of the prorenin in rats does not
cause renal fibrosis, whereas leads to myocardial hypertrophy,
proteinuria, and hypertension (Peters et al., 2008). Nguyen et al.
proposed in a well summarized review on PRR, that prorenin
may be an amplifier of fibrosis, in addition to high glucose,
inflammation, or immunological cytokines (Nguyen and Muller,
2010).
Moreover, recent studies suggest that PRR is not always devil
to kidney. Oshima et al. reported that PRR might be necessary
for the maintenance of normal podocyte structure and function.
Deficiency of the PRR inmurine podocytes resulted in disruption
of the filtration barrier and accumulation of intracellular vesicles
(Oshima et al., 2011). More studies are needed to determine the
contribution of prorenin/PRR in renal fibrosis.
Other New Members of RAS:Angiotensin A
(Ang A), Alamandine-Mas-Related G
Protein Coupled Receptor D(Mrgd)
Jankowski et al. first discovered a novel human Ang-derived
peptide, Ang A (Ala-Arg-Val-Tyr-Ile-His-Pro-Phe) with
increased level in end-stage renal failure patients compared
with healthy humans (Jankowski et al., 2007). However, Yang
et al. demonstrated that Ang A displays similar in vitro and
in vivo properties as AngII, the effect of this peptide is mediated
via AT1a receptors. Ang A might be not a naturally occurring
peptide that modulates the pressor and renal hemodynamic
effects of AngII (Jankowski et al., 2007). Additional studies are
needed to characterize the role of this peptide in the kidney
function and renal fibrosis.
By using mass spectrometry, Lautner et al. found a new mem-
ber of RAS, Alamandine. Alamandine is formed from catalytic
hydrolysis of the angiotensin A by human ACE2. The peptide
binds to Mas-related G protein coupled receptor D(MrgD), the
effects include vasorelaxation, blunting of isoproterenol-induced
heart fibrosis, and anti-hypertensive action in SHR (Lautner et al.,
2013). Alamandine is an endogenous peptide of heart tissue and
also presents in human blood (Lautner et al., 2013). Lautner et al.
revealed that nephropathic patients have increased plasmatic
concentration of alamandine. Administration of alamandine pro-
duced a long-term antihypertensive effect and decrease of col-
lagen I, III, and fibronectin accumulation in the heart (Lautner
et al., 2013). However, the role of these novel RAS components in
renal fibrosis is still lacking investigation.
Can We Block/Activate New Member of
RAS to Ameliorate Renal Fibrosis?
XNT(1-[(2-dimethylamino)ethylamino]-4-(hydroxymethyl)-
7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one) is a
recently described synthetic activator of ACE2 (Hernandez
Prada et al., 2008). It has been reported to exert various organ-
protective effects, which are attributed to the activation of ACE2.
XNT could attenuate thrombus formation, control pulmonary
hypertension, reverse cardiac fibrosis (Ferreira et al., 2009).
Administration of XNT to SHR resulted in the decrease in
blood pressure, which was also associated with improvements
in renal fibrosis (Hernandez Prada et al., 2008). However, a
recent study reported by Haber et al. showed that neither plasma
nor kidney ACE2 activity in Ang II infusion animal model was
affected by XNT. In vitro and in vivo experiments confirmed
a lack of enhancement of ACE2 enzymatic activity by XNT.
They concluded that the biological effects of this compound
are ACE2-independent (Haber et al., 2014). Studies on the
therapeutic effect of XNT in renal fibrosis are still very limited.
More observations are needed to prove its potential in treating
renal fibrosis.
Current anti-RAS therapy only has limited efficiency, partly
because of compensatory upregulation of renin expression.
Handle region peptide (HRP) mimics part of the proseg-
ment of prorenin and inhibits prorenin binding to PRR and
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FIGURE 1 | Schematic representation for the role of new members of RAS system in renal fibrosis and the potential molecules targeted RAS for
therapeutic application.
non-proteolytic activation (Suzuki et al., 2003). It was originally
considered as a PRR antagonist, which evokes much interest.
However, its therapeutic effect in vivo was still in controversial.
HRP has been shown to prevent glomerulosclerosis in diabetic
nephropathy (Ichihara et al., 2004). Afterwards, other in vivo
studies have shown no therapeutic effects, which arise skep-
ticism (Muller et al., 2008). Importantly, it is still unclear to
what degree PRR blockade adds benefits in combination with
classic RAS blockade. A recent study showed that in diabetic
TGR (mREN2)27 rats, HRP given on top of aliskiren (a direct
inhibitor of human renin), did not alter the effects of aliskiren on
blood pressure, RAS activity, or aldosterone. However, it coun-
teracted the beneficial effects of aliskiren in the kidney (te Riet
et al., 2014). In SHR, it also showed that HRP counteracted the
beneficial effects of aliskiren on blood pressure, coronary func-
tion, and cardiac hypertrophy in an angiotensin-independent
manner (van Esch et al., 2011). Thus, the therapeutic effect of
HRP for renal fibrosis is still in controversial which need more
observation.
Ang(1–7)/Mas receptor axis plays a countermeasure role to
that of angiotensin II/AT1 receptors. Ang(1–7)/Mas receptor
might be a potential target for developing oral active agonist
treating renal fibrosis. Wiemer et al. firstly described a non-
peptide mimic of Ang(1–7), compound AVE 0991 which effi-
ciently mimics the effects of Ang(1–7) on the endothelium
(Wiemer et al., 2002). Suski et al. showed that Ang(1–7)
peptidomimetic AVE0991 partially reversed atherosclerosis-
related changes in apoE(-/-) mice (Suski et al., 2013). In adri-
amycin (ADR)-induced nephropathy, treatment with AVE 0991
improved renal function and attenuated histological changes (da
Silveira et al., 2010). Ang(1–7) mimic peptide might hold a
promise in future, but it need more investigations in multiple
models of kidney injury.
Since the unsatisfied effect of RAS blockade on controlling
renal fibrosis, recently, Zhou et al. aimed to find a treatment strat-
egy to simultaneously target multiple RAS genes. They found
that overexpression of either β-catenin or Wnt ligands induced
the expression of all RAS genes. Interestingly, a small-molecule-
weight β-catenin inhibitor ICG-001 abolished RAS activation.
Meanwhile, ICG-001 therapy restored expression of nephrin,
podocin, and Wilms’ tumor 1, attenuated interstitial myofibrob-
last activation, repressed matrix expression, and inhibited renal
inflammation and fibrosis. The results indicated that blockade
of Wnt/β-catenin signaling can simultaneously repress multi-
ple RAS genes, thereby leading to the reversal of established
proteinuria and kidney injury (Zhou et al., 2015).
Further research on the contribution of those novel axes to
renal fibrosis is in warranted. The clarification of the molecular
mechanismmediating renal fibrosis may lead to the development
of new approaches in the design of agonist or antagonists of RAS
axis.
Summary
In addition to classical renin/ACE/Ang II/AT1 and AT2 axis,
recent studies have shown that multiple new members of RAS
system play critical role in both glomerularsclerosis and tubu-
larsclerosis, with synergic or antagonistic effect to classical RAS
(summarized in Figure 1). However, the exact mechanisms
through which the new players contribute to renal fibrosis are still
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unclear and the therapeutic potential targeting those members
are still in controversial. Thus, based on the review mentioned
above, the issues that need further observations include: How did
the microenvironment (lipid accumulation, albumin, inflamma-
tion etc.) change the ACE/ACE2 axis balance and how to regulate
it properly? How did the PRR been switch to pro-fibrotic fac-
tor and what is the exact role in development of renal fibrosis?
What is the role of Ang A, alamandine-MrgD in renal fibro-
sis? Shall we develop more reliable approaches to prevent or
reverse renal fibrosis with agonist or antagonists of new RAS
members? Obviously, understanding these issues will provide
more strategies for the intervention of renal fibrosis.
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